Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Pryma

Showing results (101-110 of 124) with videos related to

Pageof 13
Sort By:
Molecular Cancer Therapeutics|May 11, 2019
Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical ModelsMehran Makvandi, Hwan Lee, Laura N Puentes, et al.
The Journal of Clinical Investigation|March 7, 2018
A PET imaging agent for evaluating PARP-1 expression in ovarian cancerMehran Makvandi, Austin Pantel, Lauren Schwartz, et al.
American Journal of Clinical Oncology|June 11, 2020
ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223Mark Hurwitz, John R Buscombe, Heather A Jacene, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 7, 2018
Efficacy and Safety of High-Specific-Activity <sup>131</sup>I-MIBG Therapy in Patients with Advanced Pheochromocytoma or ParagangliomaDaniel A Pryma, Bennett B Chin, Richard B Noto, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 15, 2019
Breast Cancer <sup>18</sup>F-ISO-1 Uptake as a Marker of Proliferation StatusElizabeth S McDonald, Robert K Doot, Anthony J Young, et al.
Pancreas|May 3, 2021
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and ParagangliomaLauren Fishbein, Jaydira Del Rivero, Tobias Else, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted <sup>18</sup>F-Fluorthanatrace PET in Breast CancerAnthony J Young, Austin R Pantel, Mahsa Kiani, et al.
Communications Biology|November 18, 2022
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastomaMehran Makvandi, Minu Samanta, Paul Martorano, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 19, 2011
(124)I-huA33 antibody PET of colorectal cancerJorge A Carrasquillo, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
American Journal of Clinical Oncology|May 4, 2022
ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE TherapyCharito Love, Neil B Desai, Tony Abraham, et al.
Pageof 13

Showing results (101-110 of 124) with videos related to

Sort By:
Pageof 13
Molecular Cancer Therapeutics|May 11, 2019
Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical ModelsMehran Makvandi, Hwan Lee, Laura N Puentes, et al.
The Journal of Clinical Investigation|March 7, 2018
A PET imaging agent for evaluating PARP-1 expression in ovarian cancerMehran Makvandi, Austin Pantel, Lauren Schwartz, et al.
American Journal of Clinical Oncology|June 11, 2020
ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223Mark Hurwitz, John R Buscombe, Heather A Jacene, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 7, 2018
Efficacy and Safety of High-Specific-Activity <sup>131</sup>I-MIBG Therapy in Patients with Advanced Pheochromocytoma or ParagangliomaDaniel A Pryma, Bennett B Chin, Richard B Noto, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 15, 2019
Breast Cancer <sup>18</sup>F-ISO-1 Uptake as a Marker of Proliferation StatusElizabeth S McDonald, Robert K Doot, Anthony J Young, et al.
Pancreas|May 3, 2021
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and ParagangliomaLauren Fishbein, Jaydira Del Rivero, Tobias Else, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
Kinetic Analysis and Metabolism of Poly(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted <sup>18</sup>F-Fluorthanatrace PET in Breast CancerAnthony J Young, Austin R Pantel, Mahsa Kiani, et al.
Communications Biology|November 18, 2022
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastomaMehran Makvandi, Minu Samanta, Paul Martorano, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 19, 2011
(124)I-huA33 antibody PET of colorectal cancerJorge A Carrasquillo, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
American Journal of Clinical Oncology|May 4, 2022
ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE TherapyCharito Love, Neil B Desai, Tony Abraham, et al.
Pageof 13